Protecting Patients from Deceptive Drug Ads Act

Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text: CR S1129-1130)

Bill 119 s 652, also known as the Prescription Drug Advertising Regulation Act, aims to regulate the way prescription drugs are advertised to the public. The bill seeks to ensure that communications regarding prescription drugs are accurate and not misleading to consumers.

Under this legislation, pharmaceutical companies would be required to provide clear and transparent information about the benefits and risks of their products in any advertising or promotional materials. This includes disclosing any potential side effects or risks associated with the drug.

Additionally, the bill would establish guidelines for the use of testimonials and endorsements in prescription drug advertising. Companies would be prohibited from using misleading or false testimonials to promote their products. Overall, the goal of Bill 119 s 652 is to protect consumers from deceptive advertising practices and ensure that they have access to accurate information about prescription drugs. The bill aims to promote transparency and accountability in the pharmaceutical industry, ultimately benefiting the health and well-being of the public.